U.S. drugmaker Eli Lilly on Monday said it has appointed insider Lucas Montarce as its new chief financial officer, effective immediately.
on Monday said it has appointed insider Lucas Montarce as its new chief financial officer, effective immediately, months after former CFO Anat Ashkenazi stepped down to join Google parent
The executive appointment comes at a crucial time for Eli Lilly as it invests billions to increase manufacturing capacity and meet unprecedented demand for its diabetes and weight loss drugs - Mounjaro and Zepbound.are leaders in the burgeoning market for new weight loss drugs, which some analysts project could exceed $150 billion by the early 2030s.
Montarce, who joined Lilly in 2001, has held various finance leadership roles, including the company's head of finance for Lilly Research Laboratories and Lilly International. Most recently, he served as the president and general manager for Lilly's Spain, Portugal, and Greece hub, a position he assumed earlier this year.
In addition to his CFO role, Montarce will serve as the drugmaker's executive vice president and, receive a base salary of $1 million, and be eligible for an annual target bonus of $1 million.
Biotech And Pharmaceuticals United States Alphabet Inc Eli Lilly And Co Novo Nordisk A/S Novo Nordisk A/S Business News
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Stocks making the biggest premarket moves: KeyCorp, Starbucks, JetBlue, Eli Lilly and moreThese are the stocks posting the largest moves in the premarket.
Read more »
Deutsche Bank says Eli Lilly stock is a buy — in line with our rating on sharesThe Investing Club holds its 'Morning Meeting' every weekday at 10:20 a.m. ET.
Read more »
Healthy Returns: Eli Lilly gains momentum against Novo Nordisk in the weight loss drug marketEli Lilly may be starting to gain an edge over Novo Nordisk in the GLP-1 market. Meanwhile, Stryker will acquire artificial intelligence startup Care.ai.
Read more »
Healthy Returns: Eli Lilly gains momentum against Novo Nordisk in the weight loss drug marketEli Lilly may be starting to gain an edge over Novo Nordisk in the GLP-1 market. Meanwhile, Stryker will acquire artificial intelligence startup Care.ai.
Read more »
10 things to watch in the stock market Friday including more bullishness on Eli LillyWall Street is lower Friday morning after a strong session Thursday extended the market comeback.
Read more »
Novo Nordisk vs. Eli Lilly: Analysts weigh in as the obesity-drug battle heats upAs competition grows in the weight loss drug space, investors are questioning which company will come out on top.
Read more »